Open

Study of a Combination of Chemotherapy and Immunotherapy for Bladder Cancer

This study is to test a combination of chemotherapy drugs with an immunotherapy drug (Nivolumab), which is experimental in patients with bladder cancer. The research is to determine if surgery for muscle invasive bladder can be delayed or avoided by treatment with this combination and how it would affect the quality of life and long-term survival of participants.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

If you decide to participate in this study, you will have CT or MRI scans, cystoscopies, and physical examinations. At each visit, you will be asked questions about your health and your current medications.

Incentives

In-person visits:
6+

Total length of participation:
7 years

Looking for Specific Volunteers

Able to participate:

You have urothelial cancer of the bladder
You have urothelial cancer of the prostate urethra in men
You have no metastatic disease

Not eligible if:

You've had previous treatment with systemic chemotherapy or radiation therapy for urothelial cancer
You have an additional malignancy that has progressed or required treatment in the last 3 years
You have any condition requiring systemic treatment with steroids
You have a history of autoimmune disease

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Tracy Rose
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Bladder)
Urinary and Bladder

IRB Number

20-3643

ClinicalTrials.gov

NCT04506554

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.